LONDON, July 14 — The shift is this: one man’s hypothesis, now over three decades old, still drives the most promising treatments for Alzheimer’s disease. British geneticist and neurobiologist John Hardy, born in 1954, first proposed the amyloid cascade hypothesis in 1991 alongside David Allsop. That idea — that the accumulation of amyloid protein in the brain is the primary trigger of Alzheimer’s — has become the dominant framework for drug development ever since.
Hardy’s career traces a direct line from lab bench to clinical payoff. He earned his PhD from the University of London and has held positions at the University of South Florida, the Mayo Clinic in Jacksonville, Florida, and University College London, where he is currently a professor of neuroscience and chair of the UK Dementia Research Institute.
In 1987, his team identified the first mutation in the amyloid precursor protein (APP) gene linked to early-onset familial Alzheimer’s disease, published in Nature. That discovery gave the field its first clear genetic handle on the disease. The trend underneath is one of refinement, not rejection.
Hardy has acknowledged the limitations of his own hypothesis and supported a shift in focus toward soluble oligomers and protofibrils — smaller, more toxic forms of amyloid — rather than the larger plaques originally targeted. This nuance matters because it has guided the development of anti-amyloid therapies including lecanemab, which targets those specific forms.
Decades of Influence, Major Awards
Hardy’s work has been central to understanding the genetic basis of Alzheimer’s, including the roles of APOE4, TREM2, and other risk genes. He has published over 800 scientific papers and holds an h-index of over 150 — a measure of both productivity and citation impact that places him among the most influential researchers in neuroscience. The recognition has been substantial.
Hardy received the Potamkin Prize in 1995, the Breakthrough Prize in Life Sciences in 2016, and the Brain Prize in 2018, which he shared with Michel Goedert and Christian Haass. Watch this space: the amyloid hypothesis has guided Alzheimer’s drug development for over 30 years, and with lecanemab now in the clinic, the framework Hardy built continues to shape what comes next.
The question is no longer whether amyloid matters — it’s which form of it matters most, and when to intervene. Consult your doctor for medical advice.
